Published in Cancer Detection and Prevention 1999; 23(2):147-154.

p53 Overexpression and Mutation in Endometrial Carcinoma: Inverted Relation with Estrogen and Progesterone Receptor Status

Kenji Niwa, M.D., Toshiko Murase, M.D., Shigeo Morishita, M.D., Midori Hashimoto, M.D., Naoki Itoh, M.D., and Teruhiko Tamaya, M.D.

Department of Obstetrics and Gynecology, Gifu University School of Medicine, Gifu, Japan

Address all correspondence and reprint requests to: Kenji Niwa, MD, Department of Obstetrics and Gynecology, Gifu University School of Medicine, 40 Tsukasa-machi, Gifu-city, Gifu 500-8705, Japan.

ABSTRACT: Overexpression and mutation of p53 in 46 primary endometrial carcinomas were determined comparatively with the status for estrogen receptor (ER) and progesterone receptor (PR). Immunohistochemically p53 overexpression was found in 9 of 46 cases (20%), while eight kinds of mutations in that gene were detected in 7 of 46 endometrial carcinomas (15%), using polymerase chain reaction single-strand conformation polymorphism and subsequently direct sequencing method. Six of nine cases with p53 overexpression showed p53 mutation. All eight mutations showed single substitutions, and three cases in exon 4, one in exon 5, two in exon 6, and two in exon 7 were found. The cases with the p53 overexpression were significantly inversely related to that of ER or PR staining. Most endometrial carcinoma with p53 overexpression and/or mutation had a relatively poor prognosis and showed no reactivities of ER or PR.

KEY WORDS: endometrial carcinoma, mutation, overexpression, p53 gene, sex steroid hormone receptors.